KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Working Capital Changes: 2014-2024

Historic Other Working Capital Changes for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$5.3 million.

  • CRISPR Therapeutics AG's Other Working Capital Changes fell 543.62% to -$834,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 76.42%. This contributed to the annual value of -$5.3 million for FY2024, which is 77.24% up from last year.
  • CRISPR Therapeutics AG's Other Working Capital Changes amounted to -$5.3 million in FY2024, which was up 77.24% from -$23.2 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Other Working Capital Changes ranged from a high of $13.9 million in FY2021 and a low of -$23.2 million during FY2023.
  • Moreover, its 3-year median value for Other Working Capital Changes was -$5.3 million (2024), whereas its average is -$10.0 million.
  • In the last 5 years, CRISPR Therapeutics AG's Other Working Capital Changes soared by 180.24% in 2021 and then plummeted by 1,353.00% in 2023.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Other Working Capital Changes stood at -$17.3 million in 2020, then surged by 180.24% to $13.9 million in 2021, then slumped by 111.49% to -$1.6 million in 2022, then plummeted by 1,353.00% to -$23.2 million in 2023, then skyrocketed by 77.24% to -$5.3 million in 2024.